Home Newsfeeds Needham Reiterates Buy on Monday.Com, Maintains $230 Price Target

Needham Reiterates Buy on Monday.Com, Maintains $230 Price Target

Needham analyst Scott Berg reiterates Monday.Com (NASDAQ:MNDY) with a Buy and maintains $230 price target.

byBenzinga Newsdesk

February 14, 2023

1 minute read

Needham analyst Scott Berg reiterates Monday.Com (NASDAQ:MNDY) with a Buy and maintains $230 price target.

Turkey Has A Complicated Relationship With The West, And It May Not Be Solved By Its Upcoming Presidential Runoff

By Natan Ponieman

May 15, 2:59 PM

The political fate of Turkey still hangs in the balance as the nation’s presidential election was moved to…

TUR

BIO-key Receives $1.5M Pre-Paid, Two-Year Software Subscription Order For Its Biometric Identification Platform; Contemplates ~12% Annual Growth In Users Over The Next Year

By Benzinga Newsdesk

February 20, 10:00 AM

BIO-key® International, Inc. (NASDAQ:BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software infrastructure featuring passwordless, phoneless and token-less

BKYI

News

No, Elon Musk Isn’t Staying In A Boxabl — Here’s How Much His Main Residence In South Texas Costs

By Shanthi Rexaline

August 8, 11:33 AM

Tesla, Inc. (NASDAQ: TSLA) CEO Elon Musk may be the world’s richest person, but he calls a simple house in South Texas his main residence.

PYPL

Raymond James Thinks Haemonetics Growth Is ‘Underappreciated’

By Vandana Singh

July 1, 12:20 PM

Earlier this week, Raymond James attended Haemonetics Corp’s (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including…

HAE

Needham Reiterates Buy on Monday.Com, Maintains $230 Price Target

Related Posts

Turkey Has A Complicated Relationship With The West, And It May Not Be Solved By Its Upcoming Presidential Runoff

BIO-key Receives $1.5M Pre-Paid, Two-Year Software Subscription Order For Its Biometric Identification Platform; Contemplates ~12% Annual Growth In Users Over The Next Year

No, Elon Musk Isn’t Staying In A Boxabl — Here’s How Much His Main Residence In South Texas Costs

Raymond James Thinks Haemonetics Growth Is ‘Underappreciated’